Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

6022 - Clinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Nikolaos Tsoukalas

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

N.G. Tsoukalas1, E. Aravantinou1, K. Tsapakidis1, C. Giaginis2, M. Tolia3, I. Binas1, P. Baxevanos1, M. Galanopoulos1, M. Kiakou1, M. Tsiatas1, I. Kostakis2, C. Nikolaou1, I. Litos1, M. Liontos4, E. Tsiambas1, I. Gioulbasanis1, I. Sfiniadakis2, A. Karameris1, G. Kyrgias3, S. Theocharis2

Author affiliations

  • 1 Oncology, Veterans Hospital (NIMTS), 115 21 - Athens/GR
  • 2 First Department Of Pathology, Medical School, National and Kapodistrian University of Athens, Athens/GR
  • 3 Department Of Radiotherapy-radiation Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa/GR
  • 4 Oncology Unit, Department Of Clinical Therapeutics, Alexandra Hospital, 115 28 - Athens/GR
More

Resources

Abstract 6022

Background

Lung cancer is the first cause of cancer related deaths. RCAS1 (Receptor-binding Cancer Antigen expressed on SiSo cells) is a protein that is expressed in different types of cancer and seems to be involved in the process of the tumour cells’ escape from the immune system surveillance (immunoescape). CD3 (cluster of differentiation CD3), is an antigen that is part of the T cell receptor (TCR) complex on a mature T lymphocyte. Tumor infiltrating lymphocytes (TILs) have been correlated with patients’ survival in several neoplasms.

Methods

The aim of this study was to evaluate the clinical importance of RCAS1 and CD3 expression in non-small cell lung cancer (NSCLC). Tissue microarrays of tumor specimens from 112 patients with newly diagnosed NSCLC were constructed. The sections were stained with monoclonal antibodies against RCAS1, Ki-67 and CD3 using immunohistochemistry and they were studied through classical pathological evaluation and computerized image analysis. Correlations among RCAS1, Ki-67 and CD3 expression, clinicopathological variables and survival were analyzed. In all cases p-value ≤ 0.05 was considered significant.

Results

112 patients were included in this study with mean age 63.6 years old and 83% were males. RCAS1 expression was higher in grade III tumors comparing with grade I (p = 0.004) and grade II (p = 0.005) regardless of the histological type and in adenocarcinomas with lymphovascular invasion (p = 0.014). A positive correlation between RCAS1 and Ki-67 levels was observed (p = 0.002). There was an inverse correlation of overall survival with RCAS1 and Ki-67 levels and patients with higher expression of RCAS1 or Ki-67 had a significantly shorter survival. Also, an inverse correlation between RCAS1 expression and the percentage of CD3(+) TILs was found. Finally, a positive correlation between the percentage of CD3(+) TILs and the patients’ overall survival (p = 0.094) was observed.

Conclusions

CD3 expression was negative correlated with RCAS1 and positive with overall survival in patients with NSCLC. RCAS1 could be a useful biomarker indicating tumor aggressiveness and immunoescape of cancer cells. Further studies needed to elucidate the possible role of RCAS1 as a biomarker in immunooncology era.

Clinical trial identification

Legal entity responsible for the study

Medical School, National and Kapodistrian University of Athens.

Funding

Has not received any funding.

Editorial Acknowledgement

Hellenic Society of Medical Oncology (HeSMO).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.